
$4M+2% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $4M in 2025, compounding +36% a year since 2022 though the path has been bumpy. The trailing twelve months are already running at $5M, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$-712MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→The company lost $712M in 2025, more than the $401M it lost the year before. The losses are widening - check the Health chapter for how long the cash lasts.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
+1.8%revenue growth, FY 2025
Off the axis: 2023 earnings -215.2% - rebounds off a collapsed prior year.
→Revenue grew +2% in 2025 against a five-year average of +57%. 2023's swing into loss (-215%) sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$14MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $14M in 2025. That is the most cash the business has ever thrown off in a year. The trailing twelve months stand at $8M.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→385 cents of every sales dollar became free cash in 2025, up 2037 points since 2022 - the best conversion in its filed history.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is stock compensation, at 1607% of revenue (research and development 1162%, capital spending 16%).
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin compressed 13980 points to -15561% since 2022. The bottom line is still negative: costs below the operating line eat what is left.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of -128% and ROCE of -35% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
554.8xP/S today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 554.8x sales, the market is paying 65% less than DJT's own 4-year median of 1599.4x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
0.3%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 0.3% of annual free cash flow, less than its 4-year median of -0.7% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Debt of $970M sits against $215M of cash, or 0.9x shareholders' equity. Earnings don't currently cover the interest bill at all.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The company's own capital grew from $-67M in 2023 to $1.0B. The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Shareholders received $54M in buybacks in 2025. Stock compensation issued $59M of new shares in the same year, offsetting 100% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The share count grew 50.1% in 2025, averaging 48.0% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→DJT's return on capital is negative at -34.7% in 2025. The capital in the business is not yet earning anything back.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→DJT issued +191% more shares from 2022 to 2025 and revenue per share still fell -14%. On this measure the new shares have not paid for themselves.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Insiders bought $10,465 and sold $652,801 on the open market, a net sale of $642,336. A further 42 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30